The respective pharmaceutical partners will be commercializing the product, subject to regulatory review and approval, in the following countries:

• Turkey – Nobel Ilac A.S.
• Israel – PharmaSwiss SA
• South Africa – Adcock Ingram

“These agreements represent important milestones in expanding Eurand’s cyclobenzaprine ER franchise into new territories,” said John Fraher, Eurand’s chief commercial officer.

As announced in August 2008, Eurand signed a license and supply agreement with Daewoong Pharmaceuticals Co. Ltd, a leading South Korean pharmaceutical company. Under terms of the agreement, Daewoong will commercialize cyclobenzaprine ER in South Korea, subject to regulatory approval.

Developed using Eurand’s innovative Diffucaps® technology, cyclobenzaprine ER is a centrally acting muscle relaxant indicated as an adjunct to rest for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. Cephalon markets the product in the U.S. under the brand name Amrix®. Cyclobenzaprine ER is available for licensing in certain other countries.

About Nobel Ilac

Nobel Ilac A.S. is one of the leading pharmaceutical companies in Turkey with successful marketing and sales strategies in the domestic and international market, supported by a vertical integration of developing and manufacturing API (active pharmaceutical ingredients) and pharmaceuticals. The product portfolio of Nobel comprises self-developed/manufactured pharmaceuticals, in-licensed pharmaceuticals and OTC products. Nobel is also one of the main exporters of pharmaceuticals in Turkey. With 2200 employees throughout its subsidiaries in 15 countries, Nobel is outstanding with its global structure through which it offers its high quality services and products as it does in Turkey.

About PharmaSwiss SA

Established in 2000 and based in Zug, Switzerland, PharmaSwiss offers full third-party representation of specified drugs or portfolios from research-based pharmaceutical and biotech companies, including drug registration, promotion, sales,
compliance and pharmacovigilance. It represents several blue chip clients such as Amgen, Bristol-Myers Squibb, Wyeth
Pharmaceuticals, Ipsen, Astellas Pharma, Eli Lilly and Ferring. PharmaSwiss currently operates in Serbia, Croatia, Slovenia, Poland, Baltic countries, Czech Republic, Hungary, Romania, Bulgaria, Slovakia, Albania, Greece, Turkey and Israel. During the course of 2008, PharmaSwiss has launched operations in Hungary, Romania and Turkey and during 2009 in Poland. Development plans for the following years include also entering Russia and CIS. The company has nearly 600 employees and achieved turnover of EUR 132 million in 2008.

About Adcock Ingram

Adcock Ingram is a leading South African pharmaceutical company with a history that spans 117 years of adding value to the lives of millions of South Africans. The company has an extensive range of prescription, generic and OTC products and also provides life saving hospital equipment, diagnostic products and services. The extensive range of over-the-counter and prescription products of original research and generic medicines was recently enhanced by the addition of a range of generic antiretroviral medicines. The company’s in-house research and development facilities are approved by the South African Medicines Control Council and accredited by the World Health Organisation. The company is extending its footprint in Sub-Saharan African and international markets.